871084-80-9Relevant academic research and scientific papers
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
Barlaam, Bernard,Ballard, Peter,Bradbury, Robert H.,Ducray, Richard,Germain, Herve,Hickinson, D. Mark,Hudson, Kevin,Kettle, Jason G.,Klinowska, Teresa,Magnien, Francoise,Ogilvie, Donald J.,Olivier, Annie,Pearson, Stuart E.,Scott, James S.,Suleman, Abid,Trigwell, Cath B.,Vautier, Michel,Whittaker, Robin D.,Wood, Robin
, p. 674 - 678 (2008/09/16)
Starting from initial lead 1 containing a basic 5-substituent, optimisation of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. Representative compounds 19 and 21 inhibited phosphorylation of erbB
